The firm said that its cell-free DNA assay has shown a high positive predictive value in preliminary clinical studies involving stage IV colorectal cancer patients.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
The study made use of a high-resolution mass spec approach developed by University of Minnesota scientists that allows for untargeted discovery of DNA adducts.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
The firm believes that data from a recently published study illustrates the advantages of its technology for methylation-specific PCR assays.
Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MAP, which increases risk of CRC development.
CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.